Navigation Links
Labopharm Comments on Recent Trading Activity

LAVAL, QC, Dec. 12 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS, NASDAQ: DDSS), at the request of Market Surveillance on behalf of the Toronto Stock Exchange, today commented on the recent trading activity of its common shares. The Company is not aware of any reason for the recent trading activity other than the approaching Prescription Drug User Fee Act (PDUFA) action date for its once-daily formulation of tramadol, by which the U.S. Food and Drug Administration (FDA) could provide final approval for marketing and sale of the formulation in the United States. The PDUFA action date is January 2, 2009. The Company has not yet received any decision from the FDA. When it does, it will issue a press release.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally and its second product, a novel formulation of trazodone for the treatment of major depressive disorder, is under regulatory review by the FDA. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become an integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the uncertainties related to the regulatory process in various countries for the approval of the Company's products and the successful commercialization of the products throughout the world if they are approved. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.

SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Labopharm to host webcast presentation on novel trazodone formulation for treatment of major depressive disorder
2. Labopharms NDA for Novel Trazodone Formulation accepted for review by FDA
3. Labopharm announces change to Board of Directors
4. Labopharm Reports Results for Third Quarter Fiscal 2008
5. Labopharm to host conference call Friday, November 7, 2008 at 8:30 a.m. (ET)
6. Labopharms Once-Daily Tramadol Product Launched in South Korea, Australia, Romania and Austria
7. Labopharm to host conference call Friday, August 8, 2008 at 8:30 A.M. (ET)
8. FDA accepts Labopharms response for once-daily tramadol as complete Class 2 response
9. Labopharm Reaquires UK Sales And Marketing Rights to Its Once-Daily Tramadol Product
10. Labopharm Submits Complete Response to FDA as a Result of Outcome of Appeal Process for Once-Daily Tramadol
11. Labopharm Receives Response from FDA Regarding its Once-Daily Tramadol Product
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... ... I found that regular bras were incredibly uncomfortable," said an inventor from Bronx, ... bra." , She developed the patent-pending RECOVERY BRA for added comfort and support. ...
(Date:11/25/2015)... ... November 25, 2015 , ... An unlikely combination of recycled ... way for homeless people to have a more dignified and comfortable night’s sleep. ... they are repurposing plastic bags into sleeping mats for the homeless. The ...
(Date:11/25/2015)... CHICAGO, IL (PRWEB) , ... November 25, 2015 ... ... the cure for Tuberous Sclerosis Complex (TSC), as well as raising public awareness ... people where they need it—presented a third donation of $35,000 to bolster progress ...
(Date:11/25/2015)... ... November 25, 2015 , ... Students and parents have something ... winners of the Create Real Impact awards. California Casualty is proud to ... the tide of distracted and reckless driving, the number one killer of young drivers. ...
(Date:11/24/2015)... ... November 25, 2015 , ... Genesis Chiropractic ... Plan software creates an agreement between the practice owner and the patient that ... monitoring, notification, and projections. Click here to learn more. ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... -- WuXi PharmaTech (Cayman) Inc. ("WuXi" or the "Company") ... and technology platform company serving the pharmaceutical, biotechnology, and ... and the United States ... of shareholders held today, the Company,s shareholders voted in ... previously announced agreement and plan of merger (the "Merger ...
(Date:11/24/2015)... Calif. , Nov. 24, 2015 /PRNewswire/ ... leader in non-invasive genetic testing and the ... that it will present at the 27 ... York on Wednesday, December 2, 2015 at 1:00 p.m. ET.  Matthew Rabinowitz, ... Company,s financial results, business activities and financial ...
(Date:11/24/2015)... 2015  In the pharmaceutical industry, companies want to ... quickly uncover new insights, tactics and strategies that will ... --> However, organizations often find it is ... ensure that all rules and regulations are met to ... barrier to efficiently launching market research projects is the ...
Breaking Medicine Technology: